Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Linda M. Fredrick"'
Autor:
Jeong Heo, Yoon Jun Kim, Jin-Woo Lee, Ji Hoon Kim, Young-Suk Lim, Kwang-Hyub Han, Sook-Hyang Jeong, Mong Cho, Ki Tae Yoon, Si Hyun Bae, Eric D. Crown, Linda M. Fredrick, Negar Niki Alami, Armen Asatryan, Do Hyun Kim, Seung Woon Paik, Youn-Jae Lee
Publikováno v:
Gut and Liver, Vol 15, Iss 6, Pp 895-903 (2021)
Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P
Externí odkaz:
https://doaj.org/article/5090ec51a94c495aa641491335e33b4f
Autor:
Florence Wong, Gretja Schnell, Paul Y. Kwo, Edward Gane, Fred Poordad, Tarik Asselah, Samuel S. Lee, Christophe George, Manh Hung Le, Federico J. Mensa, Thuy Thanh Pham, C W Spearman, Betty B. Yao, Kinh Van Nguyen, Tuan V. Nguyen, Linda M Fredrick, Kris V. Kowdley, Armand Abergel
Publikováno v:
Liver International
Background & Aims Hepatitis C virus (HCV) has high genetic diversity with six major genotypes (GT) GT1‐6 and global distribution. HCV GT5 and 6 are rare with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8551028a68e2ce4357cce1d121b8f2c
https://doi.org/10.1111/liv.14535
https://doi.org/10.1111/liv.14535
Publikováno v:
Patient Preference and Adherence, Vol 2009, Iss default, Pp 195-203 (2009)
Kari S Anderson, Victoria M Mullally, Linda M Fredrick, Andrew L CampbellAbbott Laboratories, Abbott Park, IL, USAAbstract: Respiratory syncytial virus (RSV) is a significant cause of morbidity in high-risk infants. Palivizumab is proven to prevent s
Externí odkaz:
https://doaj.org/article/9d0c154ebe2d4c16bc102e4414bb3a8d
Autor:
Linda M Fredrick, Margaret Burroughs, Mario G. Pessoa, Adalgisa de Souza Paiva Ferreira, Maria P. J. S. Lima, Juvencio Furtado, Felipe Mazzoleni, Mário Reis Álvares-da-Silva, Mario Peribañez-Gonzalez, Lino Rodrigues, Márcia Guimarães Villanova, Tania Reuter, Hugo Cheinquer, Preethi Krishnan, Ecio Nascimento, Edison Roberto Parise, Giovanni Faria Silva, José Valdez Madruga
Publikováno v:
Repositório Institucional da UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Annals of Hepatology, Vol 20, Iss, Pp 100257-(2021)
Web of Science
Repositório Institucional da UNESP
Universidade Estadual Paulista (UNESP)
instacron:UNESP
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Annals of Hepatology, Vol 20, Iss, Pp 100257-(2021)
Web of Science
Repositório Institucional da UNESP
Universidade Estadual Paulista (UNESP)
instacron:UNESP
Made available in DSpace on 2021-06-25T15:08:07Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-01-01 AbbVie Introduction and objectives: Glecaprevir/pibrentasvir is a highly effective and well tolerated treatment for hepatitis C infection. Br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b131c15cca4699606ad220473abe2a9
Autor:
Kwang Hyub Han, Si Hyun Bae, Eric Crown, Yoon Jun Kim, Ki Tae Yoon, Ji Hoon Kim, Seung Woon Paik, Dohyun Kim, Armen Asatryan, Jin-Woo Lee, Mong Cho, Negar N. Alami, Jeong Heo, Linda M Fredrick, Sook-Hyang Jeong, Young-Suk Lim, Youn-Jae Lee
Publikováno v:
Gut and Liver
Background/aims Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a8039c98822e46e105ebbba12f56de0
https://pubmed.ncbi.nlm.nih.gov/34053916
https://pubmed.ncbi.nlm.nih.gov/34053916
Autor:
Julio A. Gutierrez, Eli Zuckerman, Stanley N. Cohen, Lino Rodrigues, Michael Gschwantler, Frederik Nevens, Ana Gabriela Pires dos Santos, Douglas E. Dylla, Victor de Ledinghen, Massimo Puoti, Andrew J. Muir, Jihad Slim, Linda M Fredrick, Florin Caruntu, John F. Dillon, Samuel H. Sigal
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 18(11)
BACKGROUND & AIMS: The direct-acting antiviral combination glecaprevir/pibrentasvir has been approved by the Food and Drug Administration for 8 weeks of treatment in treatment-naïve patients with hepatitis C virus (HCV) infection without cirrhosis o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f127748e820c7c327df8c4c1a6fdb1b0
https://pubmed.ncbi.nlm.nih.gov/32621971
https://pubmed.ncbi.nlm.nih.gov/32621971
Autor:
Margaret Burroughs, Preethi Krishnan, N. Mobashery, Armen Asatryan, Wenjing Lu, Negar N. Alami, Qing Xie, Mingxiang Zhang, Wen Xie, Guiqiang Wang, Lai Wei, Jeong Heo, Jidong Jia, Hari V. Kalluri, Rakesh Tripathi, Seng Gee Lim, Jinlin Hou, Wei Liu, Linda M Fredrick, Yoon Jun Kim
Publikováno v:
SSRN Electronic Journal.
Background: Glecaprevir/pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data in non-Japanese Asian patients have been minimal. Methods: Two phase 3 studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d9a0aba23177819f6b7c22c1edd9017
https://doi.org/10.2139/ssrn.3514708
https://doi.org/10.2139/ssrn.3514708
Autor:
Seng Gee Lim, N. Mobashery, Wei Liu, Yoon Jun Kim, Jidong Jia, Mingxiang Zhang, Jinlin Hou, Wenjing Lu, Lai Wei, Margaret Burroughs, Guiqiang Wang, Negar N. Alami, Rakesh Tripathi, Preethi Krishnan, Jeong Heo, Armen Asatryan, Linda M Fredrick, Qing Xie, Wen Xie, Hari V. Kalluri
Publikováno v:
The lancet. Gastroenterologyhepatology. 5(9)
Glecaprevir-pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data for glecaprevir-pibrentasvir in non-Japanese Asian patients have been minimal. The aim of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::850aefa6f813292a8a1a80e3edd56f6e
https://pubmed.ncbi.nlm.nih.gov/32682494
https://pubmed.ncbi.nlm.nih.gov/32682494
Autor:
Emily O. Dumas, John F. Dillon, Federico J. Mensa, Krzysztof Tomasiewicz, Christophe Hézode, Gregory J. Dore, Linda M Fredrick, Jason Grebely, Michael Gschwantler, Franco Felizarta, Brian Conway, Negar N. Alami
Publikováno v:
The International journal on drug policy. 66
International guidelines recommend treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID), including those on opioid substitution therapy (OST). The pangenotypic combination of glecaprevir and pibrentasvir has shown high sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f78d76b857158d67b24a3ef3dfee223
https://pubmed.ncbi.nlm.nih.gov/30735896
https://pubmed.ncbi.nlm.nih.gov/30735896
Publikováno v:
Future Virology. 10:949-959
ABSTRACT Aim: We examined the literature for the efficacy, safety and tolerability of lopinavir/ritonavir (LPV/r)-based regimens in antiretroviral therapy naive HIV-1-infected subjects with advanced disease. Materials & methods: Virologic and immunol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c327bfcf0e1ae179d50ffb35da29703
https://doi.org/10.2217/fvl.15.66
https://doi.org/10.2217/fvl.15.66